ATTRACT is the first international initiative to accelerate drug development for rare cancers through cross-border clinical academic research.
Rare cancers account for as many as 20% of new cancer cases. Yet, for most of them, there are hardly any specific, effective drugs available, leaving patients with limited or no treatment options. Main hurdle for rare cancer drug development is the small patient populations, resulting in limited interest from the industry and difficulties in setting up clinical trials with adequate statistical power. International collaborations are necessary and require appropriate funding.
Therefore, 6 European anti-cancer charities join forces and launch the ATTRACT 2025 call to stimulate international research on the treatment of rare cancers: Anticancer Fund (Belgium), Scientific Foundation of the Spanish Association Against Cancer (Spain), Fondation ARC (France), Kom op tegen Kanker (Belgium), KWF Dutch Cancer Society (the Netherlands) and, joining the consortium for this new edition, Rising Tide Foundation for Clinical Cancer Research (Switzerland).
For more information, please refer to the documents below.
ATTRACT 2025 will be implemented through a two-stage submission procedure: pre-proposals and full proposals through the Fondation ARC Submission System exclusively.
The call-text, specific guidelines for applicants and a preview of the pre-proposal application form will be announced prior to opening of the call. A dedicated Question & Answer Session (webinar) for applicants will be held online second half of September.
PROVISIONAL TIMELINE
Application Open Pre-proposal: 9 Sep 2024
Application Deadline Pre-proposal: 11 Oct 2024, 3pm CET